Bausch & Lomb may be worth about $28 a share in takeover - analyst
Financial analyst predicts Bausch & Lomb (BLCO) could be worth $28/share in a potential takeover, with private equity ...
Private Equity Interest Signals Upside for Bausch + Lomb: A Buy Rating Justified
In a report released yesterday, Larry Biegelsen from Wells Fargo assigned a Buy rating on Bausch + Lomb Corporation (BLCO – Research ...
Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely
Bausch Health is rumored to be looking to sell its Bausch + Lomb business, which will ease bankruptcy concerns and upgrade ...
Future Market Insights3d
Ophthalmic Eye Drop Market to Reach USD 25,876.4 Million by 2034, Expanding at a CAGR of 4.7%
The global ophthalmic eye drop market is poised for steady growth over the next decade. The market, which was valued at USD ...
Bausch & Lomb And Edgewise Therapeutics Are Among Top 7 Mid Cap Stock Gainers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
Federal Reserve's rate cut boosted tech, construction, industrial, machinery, and financial sectors. Top-performing mid-cap ...
Bausch & Lomb Sues Competition Over Copycat Formulation and 'Confusingly Similar' Product Name
This suit was surfaced by Law.com Radar, ALM's source for immediate alerting on just filed cases in state and federal courts.
Nasdaq3h
Here's Why Bausch Health Stock Gained 14.7% in a Week
Bausch + Lomb BLCO. The industry declined 0.6% during this timeframe. The sale, intended to separate both companies, is stuck for quite some time now. Hence, reports of BHC moving forward have ...
Medscape1d
Selecting Between Gatifloxacin and Moxifloxacin Drops in Ambulatory Ophthalmic Surgery
Michael K. Jensen, B.S.Pharm., M.S., is Clinical Associate Professor of Pharmacy Practice, College of Pharmacy, University of Utah, Salt Lake City, and Clinical ...